Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy
TL;DR
Imagine if scientists could take a small sample of your skin, turn those cells into the exact type of brain cells that are dying in ALS, and then test hundreds of potential medicines on them in a lab dish. That's essentially what this research accomplished. Scientists took skin cells from 100 people with ALS, converted them into motor neurons (the brain cells that control muscle movement), and discovered that these lab-grown neurons died in the same way as they do in actual ALS patients. When they tested over 100 drugs that had failed in human trials, 97% also failed in their lab model - proving their system works like the real disease. Most importantly, they found a combination of three drugs that kept the neurons alive longer, offering new hope for treatment.
Heterogeneous and predominantly sporadic neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), remain highly challenging to model. Patient-derived induced pluripotent stem cell (iPSC) technologies offer great promise for these diseases; however, large-scale studies demonstrating accelerated neurodegeneration in patients with sporadic disease are limited. Here we generated an iPSC library from 100 patients with sporadic ALS (SALS) and conducted population-wide phenotypic screening. Motor neurons derived from patients with SALS recapitulated key aspects of the disease, including reduced survival, accelerated neurite degeneration correlating with donor survival, transcriptional dysregulation and pharmacological rescue by riluzole. Screening of drugs previously tested in ALS clinical trials revealed that 97% failed to mitigate neurodegeneration, reflecting trial outcomes and validating the SALS model. Combinatorial testing of effective drugs identified baricitinib, memantine and riluzole as a promising therapeutic combination for SALS. These findings demonstrate that patient-derived iPSC models can recapitulate sporadic disease features, paving the way for a new generation of disease modeling and therapeutic discovery in ALS.
- 1Generated an iPSC library from 100 patients with sporadic ALS and demonstrated that motor neurons derived from these patients showed reduced survival and accelerated neurite degeneration compared to controls
- 2Screening of over 100 drugs previously tested in ALS clinical trials revealed that 97% failed to mitigate neurodegeneration in the SALS model, reflecting real clinical trial outcomes
- 3Identified a promising therapeutic combination of baricitinib, memantine and riluzole that significantly increased survival of SALS motor neurons
- 4Demonstrated that SALS motor neurons exhibited transcriptional dysregulation consistent with postmortem spinal cord tissues from ALS patients and showed pharmacological rescue by riluzole
- 5Established the first validated model of sporadic ALS using patient-derived iPSCs that recapitulates key disease features and correlates with donor survival
Adversarial AI reveals mechanisms and treatments for disorders of consciousness
Imagine your brain is like a city with millions of roads and traffic systems. When you're awake and conscious, traffic flows in complex, coordinated patterns. In a coma, something has gone wrong — but we've never had a great way to figure out exactly which roads are broken or how to fix them. This study built a very smart AI that learned to tell the difference between 'awake brain' and 'coma brain' by studying hundreds of thousands of brainwave recordings. Then, like a detective, the AI was pitted against a simulated model of the brain to figure out: what changes in the brain's wiring would explain the difference? The AI figured out — on its own, without being told — that two key things go wrong in a coma: a specific circuit deep in the brain (called the basal ganglia indirect pathway) gets disrupted, and the brain's 'braking system' (inhibitory neurons) starts working too hard in the wrong places. The researchers then checked these predictions against real patient data, and both checked out. The AI also suggested that zapping a specific deep brain region with high-frequency electrical pulses might help wake people up — and early evidence from human patients supports this idea.
Gene conversion empowers natural selection in a clonal fish species
Unfortunately, the content of this research abstract could not be accessed due to paywall restrictions. Without being able to read the actual findings about gene conversion in clonal fish species, I cannot provide an accurate explanation of what the researchers discovered or why it matters.
Direct detection of an asteroid’s heliocentric deflection: The Didymos system after DART
NASA crashed a spacecraft into an asteroid moon called Dimorphos in 2022, and scientists have now measured that this impact actually nudged the entire asteroid system slightly off its path around the Sun. This is the first time humans have measurably changed how a celestial body orbits the Sun, proving that we can potentially deflect dangerous asteroids heading toward Earth.
The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression
Think of your brain as having billions of tiny locks and keys. One particular lock — called the AMPA receptor — sits on brain cells and helps them talk to each other using the chemical glutamate. In people with hard-to-treat depression, this study found that those locks are less plentiful than normal, especially in emotional brain regions. When doctors gave these patients ketamine, it actually changed how many of those locks were available on the cell surface — and the bigger that change was, the better the patient felt. So ketamine isn't just temporarily numbing pain; it appears to be physically restoring a broken communication system in the brain. The scientists confirmed this by using a special brain scan (PET scan) with a radioactive tracer that literally glows where those AMPA receptor locks are located, letting them count them in real time in living people.